zurletrectinib (ICP-723)

News alerts, weekly reports and conference planners

Company:

InnoCare

Drug class:

pan-TRK inhibitor

Related drugs:

‹

›

NTRK3 fusion	Solid Tumor	NTRK3 fusion	Solid Tumor	ICP-723 Sensitive: C3 – Early Trials ICP-723 Sensitive : C3	ICP-723 Sensitive: C3 – Early Trials ICP-723 Sensitive : C3
NTRK2 fusion	Solid Tumor	NTRK2 fusion	Solid Tumor	ICP-723 Sensitive: C3 – Early Trials ICP-723 Sensitive : C3	ICP-723 Sensitive: C3 – Early Trials ICP-723 Sensitive : C3
NTRK1 fusion	Solid Tumor	NTRK1 fusion	Solid Tumor	ICP-723 Sensitive: C3 – Early Trials ICP-723 Sensitive : C3	ICP-723 Sensitive: C3 – Early Trials ICP-723 Sensitive : C3

Associations
(3)